Contents

1. Headlines 1

2. News India 2

3. News China 6

4. News Japan 9

5. Editorial 12

NEWSLETTER

TT Consultants is an ISO-27001 and ISO-9001:2008 certified Intellectual Property Consulting

firm providing services in over 20 countries worldwide to more than 500 Companies, universities

and research institutes with several offices in three countries i.e. Taiwan, US and India and strong

client base in US, Canada, Europe, Japan, Singapore, South Korea, Taiwan and India, we strive

towards providing our clients global and world-class services.

We provide patent litigation support, patent prosecution support, licensing support, patent

acquisition support, technology transfer consulting, patent portfolio management and other legal

support services to leading patent law firms, companies, universities, research institutes and

intellectual property owners.

© TT Consultants, 2012. All rights reserved – privileged and confidential

HEADLINES INDIA

India revokes Roche patent in new blow for Big Pharma

India's Cipla cuts price of 3 more cancer drugs

India Publishes Draft Guidelines f or Patenting Of TK and Biological Material

India revokes patent on Merck's asthma drug

'Amul' loses trademark battle against US giant in court

ASSOCHAM suggest formation of National IPR Strategy Authority

India scores lowest on intellectual property protection - index

Patent laws key to drug innovation, argues report

American Court rules against confidentiality for Cadila’s ‘in -house’ Indian

counsel

HEADLINES CHINA

EPO and SIPO launch Chinese-English machine translation for patents

Global IP Filings Continue to Grow, China Tops Global Patent Filings

East Asia faces unique challenges, opportunities for stem cell innovation

China’s new approach to renewable energy

Light at the end of the tunnel: trademark squatting in China

China Officially Recognizes Napa Valley Wines

HEADLINES JAPAN

Japan, China pay a high price

Japan gives patent for Medgenics IFNa pump

Astellas-UCB rheumatoid arthritis therapy wins marketing approval in Japan

Bristol-Myers, Pfizer win approval for Eliquis in Japan

Novartis future growth prospects secured by industry -leading pipeline

Roche reports positive studies of MabThera given by subcutaneous injection

Govt To Mandate Price Cuts On Popular Off -Patent Drugs

EDITORIAL

The prime solution - Invalidation search

INDIA

CHINA

JAPAN

EDITORIAL

Page 2 of 13

© TT Consultants, 2013. All rights reserved – privileged and confidential

Lupin bags final approval

from USFDA to market

generic contraceptive

tablets

If you use ‘Xerox’ the way

you use ‘zipper,’ our

trademark could be left

wide open

India announced

National Policy on

Electronics 2012; wants to

rival China

AstraZeneca unveils

antiplatelet drug Brilinta

in India

After India, now

Indonesia introduces

Patent Licenses for

Generic Versions of

Drugs

India revokes Roche patent in new blow for Big Pharma

The Intellectual Property Appellate Board (IPAB) cited a lack of

evidence that the drug was any better than

existing treatments and its high price as

reasons for the decision. Pegasys was the first

medicine to win protection in 2006 under

India's new patent regime and the revocation

will rekindle tensions between New Delhi and

global drug makers worried by the country's

tough stance.

The decision follows another high-profile setback for the industry in

March, when India granted the first ever compulsory licence to domestic drug

maker Natco (NATP.NS) to sell cheap copies of Bayer's (BAYGn.DE) cancer

drug Nexavar.

Read More>> Go to the top>>

India's Cipla cuts price of 3 more cancer drugs

Cipla Ltd. -- one of India's largest generic-drug manufacturers--said

Thursday it is cutting prices for three cancer medicines it sells in India by up

to 63%. Cipla is cutting prices of these cancer drugs to make them "affordable

and accessible" for patients, Cipla Chairman Y.K. Hamied said in a statement.

The price of Erlocip, a generic version of Roche Holding AG

(RHHBY)'s lung-cancer treatment Tarceva, has been reduced by 63% across

various strengths. Now 30 tablets of Erelocip 150 will cost 9,900 rupees

($181) versus 27,000 rupees earlier. The prices of docetaxel--used in the

treatment of breast, lung and other cancers--and capecitabine have been

halved, Cipla added in the statement.

Read More>> Go to the top>>

India Publishes Draft Guidelines for Patenting Of TK and

Biological Material

The government of India has released a set of draft guidelines to be

followed in the patenting of traditional knowledge and biological material.

NEWS INDIA

Patent Invalidation

Search

We ‘scour the earth’

when it comes to

searching for prior art

in order to invalidate a

troublesome patent.

We have helped

several US and Asian

companies save huge

litigation costs by

uncovering highly

useful prior arts. We

have Mandarin,

Japanese and Korea

native searching

capability. We are a

preferred choice for

companies involved in

complex patent

litigation and have

represented many Joint

Defense Groups

(JDGs) in such cases to

identify relevant prior

art for invalidating

potentially dangerous

patents.

Page 3 of 13

© TT Consultants, 2013. All rights reserved – privileged and confidential

Comments are due by 22 November. “It has been reported that the Indian

Patent Office is granting patents on the use of traditional knowledge (TK) of

India, particularly relating to the Ayurveda, Unani and Siddha systems of

medicine, etc. and patents have been granted on inventions related to

biological resources obtained from India without taking adequate care to

observe the mandate of law,” the draft guidelines state.

The guidelines mention India’s primary role in a range of international policy

developments related to TK and genetic resources. Pending patent

applications involving traditional knowledge are published on.

Read More>> Go to the top>>

India revokes patent on Merck's asthma drug

Indian Patents Office has revoked a patent for an asthma drug held by

US-based Merck & Co following a challenge

from domestic pharma firm Cipla. In an order,

Assistant Controller of Patents & Designs T V

Madhusudhan revoked the patent on the

ground that it lacked invention.

"The sole process claim also in its

entirety is not inventive as the said claim does not describe any inventive

feature," the order said. "In view of the above conclusion I hereby order that

the patent bearing number 246328 is revoked," Madhusudhan said in his

order.

Schering Corporation, which was later acquired by Merck & Co, had

applied for patent of the asthma drug in February 2004, and the Indian Patents

Office had granted the patent in March 2011. Cipla had challenged the patent.

Read More>> Go to the top>>

'Amul' loses trademark battle against US giant in court

The Gujarat High Court has refused to set aside an order which

cancelled Amul's registration of its trademark 'TRIX', on which a US firm has

claimed its right. In July this year, the Intellectual Property Appellate Board

had directed Registrar of Trademarks to cancel Amul's registration of TRIX

trademark.

NEWS INDIA

Patentability Search

A thorough patentability

assessment search conducted

on an exhaustive list of

patent and non-patent

databases. We offer

innovative search reports

that come along with a key

feature chart and many value

additions offered by none

other in the industry. This

service is being extensively

used by the best research

institute of Asia, several

national universities of

Taiwan, top law firms in the

US and 5 fortune 500

companies to name a few.

Page 4 of 13

© TT Consultants, 2013. All rights reserved – privileged and confidential

A Division Bench of Chief Justice Bhaskar Bhattacharya and Justice J

B Pardiwala, in a recent judgement, dismissed the petition filed by Kaira

District Cooperative Milk Producers Union Ltd, owner of Amul, seeking

cancellation of trademark 'TRIX' registered in favour of US food giant

General Mills.

Read More>> Go to the top>>

ASSOCHAM suggest formation of National IPR Strategy

Authority

Report by India Education bureau, New Delhi: The Associated

Chambers of Commerce and Industry of India (ASSOCHAM) has suggested

establishment of National Intellectual Property Right (IPR) Strategy Authority

to Department of Industrial Policy & Promotion (DIPP) in the context of fast

changing trade environment driven by global competition, innovation risks,

short product life cycle, rapid changes in technology involving huge

investments in Research & Development and human resource.

The proposed Authority should be aiming of aligning towards

achieving a target of 50,000 patent applications filed in India in 2015 and 1,

50,000 in 2020. Similar targets should also be set for filing of design and trade

mark applications.

Read More>> Go to the top>>

India scores lowest on intellectual property protection - index

The index prepared for the group's Global Intellectual Property Center

scored 11 countries on a point scale from

zero to 25, with the United States receiving

the highest overall tally of 23.73 and

Britain coming in second at 22.40.

India was last with 6.24 points,

reflecting its low scores in each of the five

categories examined by Pugatch

Consilium, an international research and analysis firm that specializes in the

knowledge economy. China was tenth with a score of 9.13, below Brazil with

9.57 points and Russia with 11.17.

The new index is intended as a tool for U.S. policymakers to push for

tough protections of U.S. copyrights, patents and trade secrets in free trade

NEWS INDIA

Freedom to Operate

Search

We provide a

proactive patent

study for mitigating

the risks involved

before entering a

new jurisdiction and

have the capability

to search in various

geographies

including most of

the Asian countries

and some European

countries. Our

experienced

professionals

perform an in-depth

search and very

closely examine the

prior art vis-à-vis the

product features.

Claim charts are

prepared based

upon the national

patent laws.

Page 5 of 13

© TT Consultants, 2013. All rights reserved – privileged and confidential

agreements and other international talks.

The United States, with some of the strongest copyright, patent and

trademark protections in the world, has a total stock of intellectual property

valued at around $5.8 trillion.

Read More>> Go to the top>>

Patent laws key to drug innovation, argues report

Pharmaceutical innovation in middle-income countries such as Brazil

and India could be boosted by stronger

enforcement of intellectual property laws and by

building up research capacity, says a report.

The report by global consultancy Charles

River Associates has identified the conditions

required to encourage innovation in middle-

income countries by evaluating government policies that promote investment

in local innovative activities in the biopharmaceutical field.

Commissioned by the International Federation of Pharmaceutical

Manufacturers & Associations (IFPMA) — an NGO representing the

pharmaceutical, biotechnology and vaccine sectors — the document was

released at the 26th IFPMA Assembly last month (31 October).

Read More>> Go to the top>>

NEWS INDIA

Structure Sequence

Search

When you request a

chemical structure/

substructure search,

our domain specific

searchers with

extensive experience

perform patent

searches and deliver

insightful results for

compounds matching

the query structure,

as well as for

compounds

containing the query

structure as a subset

(substructure) of a

larger structure.

Page 6 of 13

© TT Consultants, 2013. All rights reserved – privileged and confidential

EPO and SIPO launch Chinese-English machine translation

for patents

Breaking new ground in providing access to the most comprehensive

technological information, the European

Patent Office (EPO) and the State Intellectual

Property Office of the People's Republic of

China (SIPO) today launched the Chinese-

English component of the EPO's free

automatic translation service Patent Translate.

As a result, the collections of the two largest languages in patents are

now united as full-text documents on the same website through the EPO's

global patent database, Espacenet, and linguistically accessible for innovators

from both regions using a single tool, Patent Translate. Under the new

arrangement with SIPO, Espacenet has grown by 4 million Chinese language

Read More>> Go to the top>>

Global IP Filings Continue to Grow, China Tops Global Patent

Filings

A new WIPO report shows that while the global economy continued to

underperform, intellectual property (IP) filings worldwide kept growing

strongly in 2011. It also finds that China’s patent office became the largest in

the world, as measured by the number of patent applications received. Before

2011, China already accounted for most filings of utility models (UMs),

trademarks and industrial designs.

World Intellectual Property Indicators 2012 shows that patent filings

worldwide grew by 7.8% in 2011, exceeding 7% growth for the second year

in a row. Similarly, UM, industrial design and trademark filings increased by

35%, 16% and 13.3%, respectively.

Read More>> Go to the top>>

East Asia faces unique challenges, opportunities for stem cell

innovation

Tension is the theme running through the new consensus statement

issued by the Hinxton Group, an international working group on stem cell

research and regulation. Specifically, tension between intellectual property

policies and scientific norms of free exchange, but also between eastern and

NEWS CHINA

Patent Drafting &

Illustrations

A well drafted patent

is the key to a strong

patent and holds the

highest chances of

being accepted by the

National Patent

Office. Our

experienced and

technically trained

professionals do a

comprehensive

understanding of the

subject matter and use

their exceptional

communication skills

to elucidate the

invention and the draft

is by default reviewed

by an Indian Patent

Attorney. Further, the

draft is reviewed by

respective filing

country Patent

Attorney.

We have Illustrators

who are well

conversant with the

rules of USPTO, PCT

and other National

Patent Offices.

Page 7 of 13

© TT Consultants, 2013. All rights reserved – privileged and confidential

western cultures, national and international interests, and privatized vs.

nationalized health care systems. The consensus, titled Statement on Data and

Materials Sharing and Intellectual Property in Pluripotent Stem Cell Science

in Japan and China, was released on the Hinxton Group's website on

November 19, 2012.

"China and Japan are among the world's leading nations in stem cell research,

but because of challenges distinct from western nations, they are dramatically

underrepresented in terms of patents and licensing,"

Read More>> Go to the top>>

China’s new approach to renewable energy

Chinese companies are using innovative business models to change the

cost structures and capabilities

involved in delivering renewable

energy technology. Through strategic

partnerships with technology-led

companies in the US and Europe, they

are rapidly reducing the cost of

production and effectively entering the

value-added parts of the global

technology economy.

In the popular imagination, China’s industrial base is largely built on

agriculture and manufacturing. This is still generally true. Agriculture

employs an enormous proportion of the workforce and vast lands are

dedicated to the painstaking process of growing rice or harvesting wheat.

Read More>> Go to the top>>

Light at the end of the tunnel: trademark squatting in China

Trademark squatting has been a nightmare for many overseas

trademark owners for a long time, and more so in recent years. Our partner,

Kenny Wong, published an article last month in Intellectual Property

Magazine, titled "Kung fu trademark hustle", in which he says there are

encouraging signs that we may be seeing light at the end of the tunnel.

Following the Trademark Office, the Chinese judiciary has also openly

acknowledged the problem. On December 3, the Beijing No. 1 Intermediate

People's Court held a press conference to report on their study into "the cause,

NEWS CHINA

Patent & Trademark

Filing in India

Our Indian IP

Prosecution Partner –

Talwar Advocates

established since 1983,

handles patent and

trademark filing in the

Indian Patent Offices.

The firm has the

infrastructure and

resources to take on

the whole range of

conventional and non-

conventional IP issues

and offer clients

comprehensive

services in structuring

and securing a patent

portfolio. The firm

possesses the distinct

advantage of filing

Patents, Trademarks

and PCT National

Phase applications

electronically in Indian

Patent Office.

Page 8 of 13

© TT Consultants, 2013. All rights reserved – privileged and confidential

Utah Hosts China-U.S.

Intellectual Property

Rights Roundtable

BSA: Global software

theft totaled $63.4 billion

last year

Court finds copyright of

Buddha design valid

TechFaith Sues Samsung

for Patent Infringement

In Search of 'Dexter':

Why You Can't Buy

Pirated DVDs in China

Anymore

characteristic and judicial response to trademark squatting". Vice president

Chen Rui, a supervisor of intellectual property cases at the intermediate court

and the leader of the task force, said that the courts should fully exert their

judicial function by aiming to deter squatting activities when they interpret

and apply the law.

Read More>> Go to the top>>

China Officially Recognizes Napa Valley Wines

For more than a decade, Napa Valley vintners have been exporting

wine to China; and now, one of the most recognizable wine regions in the

world will be the first acknowledged with Geographic Indication (GI) status in

China. Geographical indications are used in all countries to act as a

certification of authenticity. This is the first time that China has granted a GI

recognition to any wine region outside of its own borders.

“Being first speaks volumes to what people think about Napa Valley,”

said Terry Hall of the Napa Valley Vintners. The Napa Valley Vintners

brokered the deal, working with the Chinese government for nearly 14 years.

The new GI status step will help prevent Napa Valley knockoffs and

counterfeiting of labels and allow for consumer protection in China's rapidly

growing market.

Read More>> Go to the top>>

NEWS CHINA

Claim Chart

Preparation

This search helps in

identifying the potential

infringers of a particular

patent portfolio. Over

the years, we have

evolved an innovative

and effective strategy to

identify infringing

products/standards and

ascertaining the

infringement. This

service is used by a

leading semiconductor

manufacturer and some

fortune 500 companies

across the globe.

Page 9 of 13

© TT Consultants, 2013. All rights reserved – privileged and confidential

Japan, China pay a high price

Confirmation of the costly economic consequences of the continuing spat

between Japan and China over who owns a tiny string of remote uninhabited

rocky islets in the East China Sea came with the publication of Japan's

September trade figures. They showed an unprecedented deficit of $7 billion

as exports dropped by 10.3 percent, thanks to the global slowdown and to

Beijing's determination to teach Tokyo a lesson.

Can China and Japan really be contemplating the madness of going to war

over who owns this small real estate? Two months ago, most commentators

expressed confidence that the row would soon blow over, but it is continuing

with new bellicose words, provocative actions and political tensions between

the once and future economic powers. New leaders settling in in Beijing dare

not risk being seen as weak, and Tokyo's nationalists will keep up the

pressure. When and how will it end?

Read More>> Go to the top>>

Japan gives patent for Medgenics IFNa pump

Medgenics received a Notice of Allowance from the Japanese Patent

and Trademark Office for key claims protecting the use of Medgenics'

Infradure Biopump technology for the delivery of interferon alpha (IFNa).

Medgenics is developing Infradure as a new approach to provide sustained

and patient compliant interferon therapy to address unmet needs in the

treatment of hepatitis B, C, and D.

Similar claims protecting Medgenics' Infradure technology have been

granted or allowed in other large Asian markets including, China, Korea and

Australia. In addition, these countries have allowed broad claims to

Medgenics protecting the core Biopump technology for production and

delivery of proteins. Patents covering core Biopump technology for a

genetically modified dermal micro-organ have already been granted to

Medgenics in the US and in the EU.

Read More>> Go to the top>>

Astellas-UCB rheumatoid arthritis therapy wins marketing

approval in Japan

Astellas Pharma and UCB have announced the marketing approval of Cimzia

(certolizumab pegol) to treat rheumatoid arthritis (RA) in Japan. The

NEWS JAPAN

Patent Watch

The patent alert service is

for clients who wish to

remain updated about the

latest patents filed in their

preferred field of invention.

It is a practical step taken by

most of the companies who

desire to keep track of the

new and improved

formulations and adjuvant

relating to their field of

interest or in respect to a

competitor's patents.

Accordingly, we endeavor

to observe patents

continually and provide

regular updates to our

clients. Further, our search

includes online product

directory and other non

patent literature available.

Page 10 of 13

© TT Consultants, 2013. All rights reserved – privileged and confidential

Japanese Ministry of Health, Labor and Welfare has approved Cimzia as a

200mg syringe for subcutaneous (s.c.) injection to treat adult RA patients who

failed to respond to conventional treatment.

The only PEGylated Fc-free anti-TNF is designed in the form of a prefilled

syringe that enables self-administration by RA patients. Adult patients can be

administered with 400mg s.c. of certolizumab pegol at weeks zero, two and

four, subsequent to 200mg every two weeks, while 400mg every four weeks

s.c. can be considered for maintenance dosing.

Read More>> Go to the top>>

Bristol-Myers, Pfizer win approval for Eliquis in Japan

Bristol-Myers Squibb and Pfizer have announced the approval of

Eliquis (apixaban) anticoagulant for the prevention of ischemic stroke and

systemic embolism in patients suffering from nonvalvular atrial fibrillation

(NVAF) in Japan.

The Japanese approval of the anticoagulant is based on ARISTOTLE,

the pivotal Phase 3 trial conducted in 18,201 NVAF patients, which assessed

the safety and efficacy of ELIQUIS compared to warfarin.

A subanalysis of the ARISTOTLE study also established a similar

safety and efficacy profile of ELIQUIS in Japanese patients, compared to the

overall study. Bristol-Myers Squibb intercontinental region and Japan

executive vice president and chief financial officer Charles Bancroft said,

"Today's approval of ELIQUIS is the result of our shared vision with Pfizer to

introduce a differentiated treatment option to reduce the burden of stroke in

patients with nonvalvular atrial fibrillation."

Read More>> Go to the top>>

Novartis future growth prospects secured by industry-leading

pipeline

Novartis has provided an update on its leading Research and

Development (R&D) pipeline and plans for turning these assets into

commercial success to provide the basis for continued growth of the Group

through 2017. Continuing R&D productivity in the Pharmaceuticals Division

has fueled an industry-leading pipeline with 139 projects in clinical

development with more than 73 New Molecular Entities (NMEs) across a

multitude of disease areas. Highlights include RLX030 and LCZ696 in heart

NEWS JAPAN

Patent Landscape

Analysis

With the help of our

technical experts,

experienced patent

searchers and IP tools

developed in-house, we

have been able to

provide valuable

reports to our clients.

Our reports have

enabled several

technology companies

across the world to

take important strategic

decisions. We have

performed patent

landscape studies for

one of the leading

semiconductor

companies in the US

and a top LED

manufacturer of Asia

to name a few.

Page 11 of 13

© TT Consultants, 2013. All rights reserved – privileged and confidential

failure as well as AIN457 in psoriasis and multiple sclerosis. In addition, the

company will showcase a comprehensive early and late-stage pipeline of

novel oncology compounds. "As a science-driven company, Novartis is

focused on innovation to address unmet medical needs for patients around the

world." said Joseph Jimenez, CEO of Novartis.

Read More>> Go to the top>>

Roche reports positive studies of MabThera given by

subcutaneous injection

Pivotal study data presented at ASH shows that subcutaneous

administration enables the delivery of MabThera over approximately 5

minutes without compromising MabThera’s proven efficacy and safety

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results

from two studies which showed that a fixed dose of MabThera (rituximab) can

be administered subcutaneously (SC), potentially allowing patients to spend

less time in infusion centers receiving their MabThera treatment. Specifically,

the studies showed that SC injection resulted in non-inferior MabThera

concentrations in the blood (pharmacokinetics; PK) compared with standard

intravenous (IV) infusion. Overall, SC and IV adverse event (AE) profiles

were similar and administration related reactions (ARR) were mostly of mild

to moderate intensity.

Read More>> Go to the top>>

Govt to Mandate Price Cuts On Popular Off-Patent Drugs

Off-patent name-brand drugs with continued high market shares will

face steep price cuts under a new rule to be introduced as soon as 2014 in an

initiative to curb health care costs. Off-patent drugs typically lose market

share to their cheaper generic counterparts. But in Japan, they tend to maintain

a high share even after their patents expire, primarily due to the

manufacturer's brand strength and stable supplies. As a result, generic

products account for less than 30% of the Japanese drug market.

The new rule, endorsed Wednesday by a Health Ministry panel, will

slash the prices of post-patent drugs if consumers are slow to shift to the

generic equivalent. Details, such as the timing of the price cuts, will be

discussed starting next year, with plans to implement the change as early as

April 1, 2014.

Read More>> Go to the top>>

NEWS JAPAN

Whitespace Analysis

Our White Space

analysis study comes

in handy if you are

looking at the future

of a new technology

or looking to diversify

into new avenues of

technology. We

compile and study

variety of literature

available for a

technology- filing

trends add up to our

analysis and we

provide

recommendations

and an idea of the

road ahead.

Page 12 of 13

© TT Consultants, 2013. All rights reserved – privileged and confidential

The prime solution - Invalidation search

A shrinking global economy and rapid growth in emerging countries,

infringement analysis has poised to become an essential tool for companies.

Patent troll, another concept which has emerged over the years, has further

contributed in the rise of infringement cases.

“According to the U.S. Department of Commerce, there has been a

76% increase in claims for trademark and patent infringement in the past

10 years.”

The prime solution - Invalidation search.

Conducting a prior art search could be a daunting task for most people.

Only an experienced searcher equipped with professional tools and access to

appropriate databases can perform a search to an adequate degree.

With 2000+ invalidation searches to its credit, TT Consultants

distinguishes itself with innovative and detailed methodology. We 'scour the

earth' when it comes to searching for prior art in order to invalidate a

troublesome patent. The non-exhaustive patent and non-patent databases

employed by the companies include Questel Orbit, TI, Total Patents

LexisNexis, KIPRIS, TIPO, CIPO, AUSPAT, Espacenet, PAJ, SIPO, IEEE,

IP.com, Science Direct, Springer, Pubmed, NCBI, Scirus and many others.

TT Consultants, with plenty of competitive IP services offering, has

prior art searching leading the portfolio of the company. The company has

gained victory by invalidation several potentially dangerous patents, helping

companies coming out of Patent Trolls and thus, saving millions of dollars.

Invalidation Search at TT Consultants

Multilingual Searching: Through our East Asia presence in Taiwan, we

have in-house Native Searchers from all technical backgrounds and

further, tie-ups with several native searchers/firms through which we

provide Chinese (Traditional and Non Traditional), Taiwan, Japanese,

French and German search capabilities.

Detailed Methodology: We have a detailed list of SOPs that we adopt

while conducting an invalidation search. Some of the brief SOPs include

understanding of the subject patent, file wrapper review, patent webbing,

inequitable conduct search, keyword and classification based search,

combinational search, citation analysis, inventor/assignee search, Native

search and thorough Non-patent search. The project managers crosscheck

the report quality and adherence to SOPs during the search. Further, the

identified prior art references are verified (technical relevancy and other

limitations such as date criteria, assignee, etc.) by the project manager

EDITORIAL

Technology Transfer/

Commercialization

TT Consultants is

working with several

technology companies

on patent licensing,

technology/product

commercialization, and

know-how transfer. We

have:

Established India

Business Desk for

the incubation

companies of several

national universities

of Taiwan

Tie-ups with the best

research institutes in

Asia

Successfully

commercialized

several products and

technologies in

various parts of the

world.

Page 13 of 13

© TT Consultants, 2013. All rights reserved – privileged and confidential

before mapping it into the report.

Inequitable conduct search: We offer Inequitable Conduct Search by

default in all invalidation projects. Using sophisticated and innovative

databases, we uncover priceless patents that were not reported to the one

or the other patent office but were cited during prosecution in other

countries and this can lead to an excellent settlement in your favor.

Quick Turnaround: TT Consultants has been successful on several

occasions by providing search results in a very short span of time.

Normally, the turnaround time for our invalidation search is 6 working

days but if you are looking at a weekend turnaround, that’s achievable.

Reports on Rolling Basis: The Company provides the additional facility

for the client to receive the identified prior art as they are identified. This

lets the client to better analyze the probability of finding the most relevant

prior arts.

Additional Analysis: An additional analysis is a complete analysis of all

the patents and prior arts studied during the search. The trends and pattern

for filing and publication activity of various active assignees and inventors

are studied for the technology domain. This analysis is represented as

graphs and charts making the data easy to analyze.

No Stone Unturned search: A “No Stone Unturned Search” is an

extended invalidation search conducted by a team of 4 resources for the

duration of four weeks which can be further expedited based on the

client’s requirement. Further, native searches are performed as and when

required. This gives a broad coverage to any relevant prior arts that may

exist.

Go to the top>>

EDITORIAL

Patent Acquisition

Services

Patent Acquisition/ In-

Licensing

We work closely with our

clients for acquiring the

right patents at the right

value. The support ranges

from landscape, evaluating

patent strength to gauging

enforcement value.

Patent Out-Licensing

We help our clients to

license their patents to the

right purchasers for the

right value. This includes

identifying the right

buyers, performing

infringement analysis and

other important aspects.

© TT Consultants, 2013. All rights reserved – privileged and confidential

Unsubscribe

If you do not wish to receive this Newsletter in future, please click here, else just reply this mail with the word "Unsubscribe" in the

subject of the mail.

Feedback/Suggestion

We will be happy to know your feedback & suggestion on the same. Kindly send us an email with your feedback.

Disclaimer

While every care has been taken in the preparation of this News Bulletin to ensure its accuracy at the time of publication, TT

Consultants assumes no responsibility for any errors which despite all precautions, may be found herein. Neither this bulletin nor the

information contained herein constitutes a contract or will form the basis of a contract. The material contained in this document does

not constitute/substitute professional advice that maybe required before acting on any matter.

*COPYRIGHT NOTICE:-© 2013, India. All Rights reserved with TT Consultants

Go To Top >>

WASHINGTON DC

TT Consultants LLC

1701, Pennsylvania Avenue, NW,

Washington DC. 20006

Mobile: +1.347.284.6413

Toll Free: +1.888.337.5234

Email: talwar@ttconsultants.co.in

TAIWAN

Tainan (Branch Office)

Room 410, Technology Transfer & Business

Incubation Center,

National Cheng Kung University,

No. 1 University Road, Tainan City 701

Hsinchu

Si-Soft Research Center, 1A2,

Lising 1st Road, Hsinchu City

Landline: +886-6-2368814

Email: a.srivastava@ttconsultants.co.in

INDIA

Chandigarh

Office 8, Tower B, 3rd Floor, D.L.F, I.T park

Chandigarh (U.T)-160101, India

Mobile: +91-9815006413

Email: s.goel@ttconsultants.co.in

Gurgaon

Unit number 252, 2nd floor, Tower B2,

Spaze I-Tech Park, Sector 49,

Sohna Road, Gurgaon-122002

Mobile: +91-9876196354

Email: n.mahajan@ttconsultants.co.in

Subscribe/Opt in

If you wish to receive this Newsletter in future, please click here.